It is determined whether or not cisplatin administration has a therapeutic effect with high accuracy and specificity. A method for determining an effect of cisplatin administration comprises a step a in which the expression of at least one gene selected from the group consisting of PDE3B (phosphodiesterase 3B) gene, PDGFC (platelet derived growth factor C) gene, PKD2 (polycystic kidney disease 2) gene, NRG1 (neuregulin 1) gene and LUM (lumican) gene in a biological sample collected from a subject to be diagnosed is measured, and a step b in which an effect of cisplatin administration is determined based on the expression level of the gene obtained as the measurement result.
展开▼
